

QUARTERLY ACTIVITIES & CASHFLOW REPORT

PERIOD ENDING 31 MARCH 2026

BRISBANE, AUSTRALIA, 20 April 2026: AnteoTech Ltd (ASX: ADO) (AnteoTech or the Company), a supplier of advanced material solutions to the Lithium-ion Battery (LiB) and Life Sciences diagnostic markets, is pleased to provide its Appendix 4C Quarterly Cashflow Report and Activities Update for the period ended 31 March 2026 (the “Quarter”). All financial results are in Australian dollars and unaudited.

The March 2026 Quarter was focused on commercial execution across both the Advanced Battery Technology (ABT) and Life Sciences (LS) businesses building on the capital raise completed in late January 2026, and the technical milestones and sales pipeline expansion achieved in the prior Quarter. The Company progressed sales conversion activities with a record number of product samples dispatched globally and now under evaluation.

Through the use of new marketing channels and product marketing collateral, the Company expanded its presence at key international industry forums and commenced new joint product development programs. Both technical and commercial progress was made.

HIGHLIGHTS

Advanced Battery Technologies

- **Ultranode™ 70's performance was validated by Wyon AG in coin cell testing to within 10% of AnteoTech benchmark levels. Wyon's miniature commercial format cells incorporating Ultranode™ 70 will undergo performance testing shortly. Wyon independently manages this program.**
- **Under the Joint Development and Sales Agreement with USA-based Black Diamond Structures, first customer samples of SiMRAX (Anteo™ X® + Molecular Rebar®™) were dispatched for evaluation. SiMRAX has demonstrated more than 50% higher cycle life in high silicon anode cells at ultra-low CNT loadings. Multiple additional customer requests have been received as a result of marketing.**
- **Independent third-party validation of the Company's high performance silicon anode Ultranode™ 95 performance-wise, aligned with industry requirements for drone battery applications, has now been completed by the Battery Innovation Centre (Indiana, USA) in Single Layer Pouch format. This was an important validation in a commercially relevant format when it comes to cost effective scale up. Further validation in Multi-Layer Pouch cells is underway, with cylindrical cell production planned allowing potential partner evaluation.**
- **Ultranode™ 95 has been designed to deliver a 40% improvement in specific energy at the active stack level compared with conventional graphite-based cells (i.e. 380 Wh/kg versus 272 Wh/kg), supporting drone and other high-performance battery applications.**
- **Negotiations progressed on two non-exclusive Ultranode™ 95 Joint Development Agreements with battery manufacturers supplying, or targeting supply, into US defence drone contracts and the broader drone markets.**

- The Company attended InterBattery 2026 in South Korea, supported by our distributor Kangshin and Austrade. Positive Anteo S™ sample bench scale testing feedback was received, with further samples requested, including for pilot-scale testing by one potential customer.
- AnteoTech also attended the 43rd International Battery Seminar & Exhibit in Orlando, Florida, where the Company presented “Maximizing High Silicon Anode Performance” and met with prospective customers and potential partners. Several site visits were undertaken post conference.
- Broader US market entry activities progressed, including import and EPA regulatory approvals, and distributor/ agent engagement.
- The ABT sales pipeline continued to build. As at mid-April, the Company’s sales tracking system contained 129 leads, with approximately 30% sales qualified leads and 17 samples under evaluation by potential ABT customers.

Life Sciences

- A new collaborative chemiluminescent immunoassay (CLIA) product development program commenced during the Quarter. AnteoTech signed an agreement with a large global life sciences company to develop an AnteoBind™ NXT activated magnetic particle product for the global CLIA market which is valued at approximately US\$13 billion¹. AnteoTech will receive A\$64,500 for services and materials under a 50:50 shared cost arrangement. Progress to date has been positive, with next stage of collaboration discussions expected on completion of the Initial Work Program.
- A comparative CLIA immunoassay white paper on AnteoBind™ NXT activated magnetic particles performance versus Tosyl-activated particles was published and is available at www.anteotech.com. The paper sets out in-house test results achieved of up to 1.8 times higher signal-to-blank ratios, up to 6 times lower antibody usage and activation up to 6 times faster versus the commonly used alternative, Tosyl activated particles.
- Under the Serum Institute of India (SII) five-year take-or-pay contract, a further order of ~US\$180,000 is expected by 30 June 2026, taking total FY2026 SII orders to approximately A\$550,000. During the Quarter, SII also received a new AnteoTech ELISA product sample for evaluation.
- Attended BioAsia 2026 in Hyderabad, India, as part of a TIQ/Austrade delegation. Meetings were held with the SII and a number of new potential customers. Post Quarter end, India-based business development services were secured to accelerate engagement and support sales conversion.
- AnteoTech participated in the NWR Virtual Healthcare Conference, where the Company outlined new CLIA and enzyme linked immunosorbent assay (ELISA) product opportunities and potential market entry plans.
- A potential new distributor in Japan was identified and engagement negotiations commenced in response to growing market interest.
- Continued engagement progressed with Vidcare, Fastsense, MOBIUS and other emerging diagnostic platform opportunities.

¹ Source: Markets and Markets May 2025 In Vitro Diagnostic Market: Growth, Size, Share and Trends and Confidential Pharmaceutical company

- The LS sales pipeline continued to build. As at mid-April, the Company's sales tracking system contained 79 leads, approximately 40% sales qualified leads and 16 samples under evaluation by potential customers.

Corporate

- The January 2026 capital raise settled, with 245,699,993 new ordinary shares issued at A\$0.0155 (1.55 cents) per share, together with attaching listed and unlisted options, raising A\$3.5 million net of costs.
- Scott Waddell commenced as Interim Chief Financial Officer and Company Secretary. Recruitment for a permanent appointment is ongoing.
- The Company held its Half Year FY2026 Investor Briefing Webinar.
- Strategic investment and partnership engagement initiatives continued during the Quarter.
- AnteoTech closed the Quarter with A\$3.291 million and no debt as at 31 March 2026.

AnteoTech Managing Director & Chief Executive Officer Merrill Gray commented: *"The March 2026 Quarter has seen us move firmly into focused sales execution mode. Supporting this we achieved progress across both technical validation and new market development, as we continue to build real commercial momentum.*

Our qualified sales pipeline has grown, with samples under evaluation now at their highest levels ever across both businesses. The capital raised in January 2026 has enabled us to invest in structured sales and marketing initiatives, including targeted campaigns and more detailed customer, distributor and market analysis supporting accelerated business development. These activities are already delivering tangible outcomes, including engagement with potential partners. Our focus over the coming Quarter is to convert these opportunities into sales.

The publication of our AnteoBind™ NXT CLIA white paper has been important in supporting our CLIA commercial market entry strategic planning. Our CLIA product delivers significant performance and cost benefits, and we look forward to providing further updates on our market entry plans in due course.


I was also very pleased with the positive reception we received at both InterBattery in South Korea and the International Battery Seminar in Florida. The events significantly increased our lead generation and reinforced growing demand for our products, particularly Anteo S™ in Battery Energy Storage Systems (BESS), a market experiencing strong growth especially in the United States. We were able to co-ordinate key meetings with potential customer and partners in conjunction with both conferences "

A. ADVANCED BATTERY TECHNOLOGIES

1. WYON AG EVALUATION — ANODE PERFORMANCE VALIDATED

Ultranode™ 70 electrode produced through the 10-fold manufacturing scale-up completed in the prior Quarter has been tested for cycle life and capacity retention. Performance was validated to within 10% of the AnteoTech baseline by Wyon AG (Wyon), a Swiss miniature battery manufacturer, using coin cell testing, as shown in Figure 1 below.

Wyon Coin Cell vs. AnteoTech Coin Cell



Full Coin cell	Initial CE (%)	Cycle number at 80% capacity retention (excl. formation)
AnteoTech	89.3	603
Wyon	89.0	556

Figure 1: Comparative Wyon/AnteoTech Ultranode™ 70 coin cell battery performance results

Source: ©AnteoTech 2026.

Assembly and testing of Wyon’s miniature commercial form factor cells incorporating Ultranode™ 70 is expected to commence shortly. This will provide validation of the anode under real world design and manufacturing conditions. While AnteoTech continues to support Wyon, testing is conducted independently by Wyon.

2. SiMRAX — SAMPLES DISPATCHED TO TARGET CUSTOMERS

Following execution of the Joint Development and Supply Agreement (JDSA) with Black Diamond Structures (BDS), announced in September 2025, and completion of product formulation activities during the December 2025 Quarter, the first SiMRAX market test samples were dispatched to target customers in early March 2026.

SiMRAX is an all-in-one product combining AnteoTech’s Anteo X® cross-linker with BDS’s proprietary Molecular Rebar® single walled carbon nanotube (SWCNT) dispersion technology. It is a binder strengthening system that combines high-quality dispersed carbon nanotubes with AnteoTech’s performance enhancing cross-linker additive.

SiMRAX has demonstrated more than 50% higher cycle life in high silicon anode cells at ultra-low CNT loadings², supporting significant cost reductions. The product is designed for ease of use and scalability, while also improving slurry rheology.

The dispatch of samples represents an important step in the commercialisation of this joint product, targeting battery manufacturers using greater than 15wt.% silicon anode formulations. Customer testing is underway, with results and next steps pending. Sales from SiMRAX are targeted to commence subject to customer evaluation feedback and further product refinement.

² In-house testing completed and validated by BDS.

Multiple additional requests for SiMRAX samples have been received from potential customers following targeted marketing campaigns and are currently being progressed.

AnteoTech’s ABT business cross-linker portfolio now comprises three complementary products: Anteo X[®] (a cross-linker for high silicon anodes), SiMRAX (a combined Anteo X[®] + SWCNT product) and Anteo S[™] (a cross-linker for ceramic coated separators, used across all LiBs, expanding AnteoTech’s addressable market beyond high silicon anodes).

All three products are available at sample, pilot and commercial scale from AnteoTech’s ISO 9001 certified 20,000L manufacturing facility in Brisbane, which has approximately 1 GWh per year expandable production capacity.

3. INDEPENDENT THIRD-PARTY VALIDATION OF ULTRANODE™ 95 PERFORMANCE BY THE BATTERY INNOVATION CENTRE (BIC), USA

Independent performance validation of Ultranode™ 95 has been completed by the BIC in Indiana, USA in coin cell and Single Layer Pouch (SLP) formats. Ultranode™ 95 results for cycle life, energy and capacity retention meet industry requirements for drone applications and align with AnteoTech’s benchmark performance for Ultranode™ 95, as shown in Figure 2 below.

All cells were tested using the same cathode and electrode configuration, with smooth scale-up of Ultranode™ 95 reported by BIC.


In its independent report dated 16 April 2026, BIC stated:

“Overall, this program has demonstrated a smooth and highly successful scale-up of a 100% silicon anode system through commercially relevant roll-to roll coatings and Single Layer Pouch cell builds”.

“Ultranode 95 represents a scalable, high-potential solution for further development and commercialisation”

Ultranode™ 95 vs. NMC811 - Current Scale-up Program

Moving from Coin to Single Layer Pouch Cells into Multi Layer Pouch Cells and to Cylindricals



Cell configuration	Formation cycle discharge capacity @C/20 (mAh/g)	1 st cycle discharge capacity @1C (mAh/g)	Initial CE (%)	Cycle number at 80% capacity retention (excl. formation)
AnteoTech - Coin Cell	2,161	1,852	89.0	227
3 rd Party - Coin Cell	2,013	1,721	88.5	225
3 rd Party - Single Layer Pouch Cell	2,014	1,691	88.3	198

Figure 2: Comparative BIC/AnteoTech Ultranode™ 95 coin cell battery and Single Layer Pouch cell performance results.
Source: ©AnteoTech2026. In-house generated.

Multi-Layer Pouch cell (MLP) format testing is currently underway. Small-scale cylindrical cell production and testing is planned. Early-stage discussions with established drone manufacturers in relation to trialling have been held with further discussions pending.

4. ULTRANODE™ 95 DRONE MARKET — JDA NEGOTIATIONS PROGRESSING

Two non-exclusive Ultranode™ 95 Joint Development Agreements (JDA) remain under negotiation with battery manufacturers that supply, or intend to supply, drone applications to the USA defence sector and other end users.

Ultranode™ 95 can deliver a 40% improvement in specific energy (Wh/kg) at the active stack level compared with conventional graphite-based cells (380 Wh/kg versus 272 Wh/kg), along with reduced cell volumes, as illustrated in Figure 3.



Figure 3: Ultranode™ 95 performance comparison
Source: ©AnteoTech2026. In-house generated.

In addition to its high performance, Ultranode™ 95 enables supply chain diversification through sourcing from established silicon suppliers across the US, South Korea and Europe.

Structured progression towards JDA execution is underway with the next step involving supply of Ultranode™ 95 anode material for evaluation and validation by potential JDA partners. Post achievement of specified test metrics with this anode material JDA discussions will move forward with execution targeted over the coming months.

5. INTERNATIONAL BATTERY CONFERENCE PARTICIPATION — SOUTH KOREA AND USA

During the Quarter, new marketing collateral was developed and deployed across email campaigns and new marketing channels, as well as at international conferences, to support the expansion of AnteoTech's market presence.

InterBattery, South Korea (11-13 March 2026):

The ABT team attended South Korea's InterBattery conference and, working with our Korean distributor, Kangshin, met with a number of potential customers and partners. Austrade supported AnteoTech's participation with inclusion in an industry seminar and networking sessions.

43rd International Battery Seminar (IBS) and Exhibit, Orlando, Florida, USA (24-26 March 2026):

AnteoTech presented "*Maximising High Silicon Anode Performance*" at IBS. The presentation covered the Company's full ABT product portfolio and included detailed technical data from an automotive customer case study, in which integration of Anteo X[®] delivered a 38% improvement in cycle life at 80% capacity retention (674 cycles versus a 489 cycles baseline) in high silicon anodes, while reducing CNT content by 50%.

While in South Korea and the USA, the team also met a number of potential customers who we are currently in negotiation with and/or who are evaluating samples. The Company continues to progress USA market entry initiatives, including import and EPA regulatory approvals, and the engagement of a distributor and/or agent.

5. ANTEO X[®] AND ANTEO S[™] — SALES PIPELINE CONTINUES TO BUILD

The Company's next generation separator performance additive, Anteo S[™], addresses one of the most pressing issues for LiB's, battery degradation leading to thermal runaway and battery fires.

Anteo S[™] has been evaluated, and remains under evaluation, by a number of potential customers. Feedback and past evaluations³ indicate that Anteo S[™] can significantly improve the safety performance of LiB ceramic coated separators and reduce the risk of thermal runaway in batteries through:

- Reduced separator shrinkage
- Improved thermochemical properties by widening the separator's thermal disintegration window (ultimate safety limit)
- Improved puncture strength and
- Improved tensile strength

This separator product is AnteoTech's first product applicable across the broader LiB market. It has attracted strong interest, particularly from South Korean and USA battery and separator manufacturers selling into the EV and BESS markets.

In 2025, BESS surpassed the automotive sector as the leading driver of USA battery supply chain investment. The convergence of declining battery production costs, strong Inflation Reduction Act (IRA)

³Source: 6/2/2025 report entitled Crosslinked ceramic separator coating (CCS) with AnteoTech's product and Undisclosed supplier boehmite – Confidential. Permission received for report results (p. 7) to be publicly release.

incentives, increasing Artificial Intelligence (AI) driven power demand and maturing grid scale project pipelines positions make BESS one of the fastest growing infrastructure asset classes globally over the next decade⁴.

This represents a new large and growing addressable market for Anteo S™ sales.

B. LIFE SCIENCES

1. CLIA PRODUCT DEVELOPMENT PROGRAM COMMENCED

On 3 March 2026, AnteoTech announced that it had signed an agreement and commenced an Initial Work Program with a large global life sciences company to develop an AnteoBind™ NXT-activated magnetic particle product for use in the global CLIA market. This market is valued at approximately US\$13 billion and forecast to grow at approximately 6% CAGR through to 2029.⁵

AnteoTech will receive A\$64,500 for services and materials under a 50:50 shared cost arrangement with the work program scheduled for completion by the end of FY2026. Solid progress has been made during the Quarter, with positive results generated and shared to date.

Successful completion of the Initial Work Program is expected to lead to a broader Joint Development Agreement in relation to CLIA market entry with discussions around this expected to commence shortly.

2. CLIA WHITE PAPER PUBLISHED - COMPARATIVE ANTEOBIND™ NXT VERSUS TOSYL ACTIVATED MAGNETIC PARTICLES FOR USE IN CLIA STUDY

During the Quarter, AnteoTech finalised and published its technical white paper entitled “*Enhancing CLIA Performance: A Comparative Study — AnteoBind™ NXT vs Tosyl-Activated Magnetic Particles*” which is available at www.anteotech.com.

The white paper sets out comprehensive test results showing the significant performance advantages and setting out the potential cost advantages of AnteoBind™ NXT when used to activate magnetic particles. Unlike conventional bioconjugation chemistries that randomly attach antibodies to particle surfaces, AnteoBind™ NXT preferentially binds antibodies in a manner that preserves the accessibility of antigen-binding arms, increasing the proportion of functionally active antibodies on the particle surface, as shown in Figure 5.

In-house testing has demonstrated 1.8 times higher CLIA signal-to-blank ratios, activation times up to six times faster, and up to six times lower antibody usage when compared with Tosyl-based bioconjugation can be achieved. Capture antibodies can account for up to 35% of total assay costs, positioning AnteoBind™ NXT activation as a compelling cost reduction opportunity for CLIA kit manufacturers and activated product suppliers to sell to customers.

⁴ Sources: IEA Electricity 2026; Benchmark Mineral Intelligence / Rho Motion; McKinsey Battery 2035; BloombergNEF; Wood Mackenzie / ACP; US EIA; SEIA; US Energy Storage Council; Solar Power World; Mordor Intelligence. Compiled April 2026.

⁵ Source: Markets and Markets May 2025 In Vitro Diagnostic Market: Growth, Size, Share and Trends and Confidential Pharmaceutical company




Figure 5: Illustration of antibody structure highlighting how AnteoBind™ NXT coated surfaces allow for improved orientation of antibodies. Source: Company data, January 2026 © AnteoTech Ltd.

The white paper is being distributed to CLIA users and market participants as part of targeted marketing campaigns and to support strategic collaboration and partnership development. A companion white paper for the lateral flow and Luminex markets was published in September 2025 and is also available. A similar white paper for the ELISA market is currently under development.

3. BIOASIA 2026 — FURTHER INDIA MARKET ENGAGEMENT

In February 2026, the AnteoTech team attended BioAsia 2026 in Hyderabad, India as part of a combined Trade Investment Queensland (TIQ) and Austrade delegation. Additional meetings were held with the Serum Institute (SII) and a range of new potential customers.

Options to establish a small, cost-effective sales presence in India to accelerate sales conversion were explored, in line with the June 2025 strategy. Post period end, India-based business development services have been secured for an initial trial period.

The Company's relationship with SII continues to strengthen. A further SII order of approximately US\$180,000 is expected during the current financial year, under the contract that is in place, taking total FY2026 SII orders to approximately A\$550,000.

SII continues to evaluate a new AnteoBind™ activated ELISA plate product sample provided in early January 2026.

4. NWR VIRTUAL HEALTHCARE CONFERENCE PRESENTATION

AnteoTech's Life Sciences business was showcased at the NWR Communications Virtual Healthcare Conference on 26 March 2026. The presentation, entitled "*Advancing Immunodiagnosics Through Surface Chemistry Modification*", set out the Company's bioconjugation expertise, the range of diagnostic immunoassay market applications offered across the AnteoBind™ product suite and their competitive advantages and the Company's potential market entry plans for the CLIA and ELISA markets at a high level.

5. SALES PIPELINE GROWTH AND BROADER MARKET ENGAGEMENT

During the Quarter, new marketing collateral was produced and targeted sales campaigns through new industry specific channels were initiated. 16 samples across the Life Sciences product range are currently under evaluation by potential customers.

In addition, a potential new distributor in Japan was identified and is being negotiated with based on growing market interest in Japan.

Engagement is continuing with Vidcare, Fastsense and MOBIUS (the ARC Research Hub for Molecular Biosensors at Point-of-Use). Platform opportunities may be particularly attractive for AnteoTech, as they can lead to multiple downstream applications in addition to recurring product sales volumes by application.

C. CORPORATE AND FINANCIALS

CAPITAL RAISE — SETTLEMENT COMPLETED

The A\$3.5 million (net of costs) capital raise announced on 27 January 2026 was settled on 4 February 2026. A total of 245,699,993 new fully paid ordinary shares were issued at A\$0.0155 (1.55 cents) per share, together with 122,849,996 listed class options (exercisable at A\$0.035 and expiring on 31 May 2026) and 122,849,996 unlisted options (exercisable at A\$0.035 and expiring 31 January 2028).

APPOINTMENT OF INTERIM CFO AND COMPANY SECRETARY

Mr Scott Waddell commenced as Interim Chief Financial Officer and Company Secretary on 2 February 2026. Mr Waddell brings more than 30 years of corporate finance experience, having previously held Chief Financial Officer and Company Secretary roles at Metallica Minerals Limited (ASX: MLM), Metro Mining Ltd (ASX: MMI) and Cape Alumina Ltd (ASX: CBX). Recruitment around a permanent appointment is ongoing.

CASH AND EXPENDITURE

As at 31 March 2026, the Company had a cash balance of A\$3.291 million with no debt.

During the Quarter, customer receipts totalled A\$294,000, resulting in net cash outflows from operating activities of A\$1.6 million.

A detailed summary of cash flows is provided in the Appendix 4C Quarterly Cash Flow Report.

Business Expenses	A\$'000
Research and Development	230
Staff, Admin and Corporate	1,322
Other	342
Total (excluding Revenue)	1,894

Capital Expenses	A\$'000
Plant and Equipment	9
Intellectual Property	62

ASX LISTING RULE 4.7C DISCLOSURE

This Quarter, A\$159,000 was paid to Related Parties, as reported in Item 6.1 of the ASX Appendix 4C (Quarterly Cash Flow Report), for directors' fees.

D. LOOKING FORWARD

The Company's overarching objectives over the June 2026 Quarter and the balance of calendar 2026 is the conversion of its LS and ABT customer sample trials/testing into sales, continued pipeline and sales growth and securing strategic partnerships and or investment. Specifically, by business:

A. LIFE SCIENCES

The Initial Work Program collaboration with the large global life sciences company in relation to a new CLIA product is on track for completion by end of FY2026, as planned. Subject to successful outcomes, a JDA is expected to be entered into around CLIA market entry. In parallel, the Company is assessing opportunities to enter the CLIA market itself working with a local toll services provider and collaborating with a well-established CLIA market distributor. The Company will also continue to progress ELISA product development through an in-house testing program. On successful development a white paper will be prepared setting out the benefits.

AnteoTech overall immunoassay market offering is growing and will be communicated in Strategic investment and partnership discussions.

New customer sales conversions including in India through the newly appointed business development resources and in Japan through a new distributor (yet to be appointed), along with new marketing collateral development, targeted sales campaigns and conference attendances are also a focus.

B. ADVANCED BATTERY TECHNOLOGIES

As previously announced, results from Wyon's commercial form factor cell evaluations of Ultranode™ 70 were expected by end of March 2026. AnteoTech advises that testing is progressing well — with Ultranode™ 70 performance validated in coin cells — however Wyon has advised that the timeline for completion of commercial form factor cell evaluations is now expected to extend beyond the June 2026 Quarter.

Over the coming Quarter the ABT team will continue to support Wyon and seek to secure commercial supply arrangements for Ultranode™ 70 working with Wyon or through AnteoTechs growing networks particularly in South Korea and the USA.

Customer evaluation feedback from the SiMRAX sample recipients is anticipated during the June Quarter with sales negotiations expected to follow where results are positive.

The two Ultranode™ 95 JDA negotiations with drone battery manufacturers are a priority for the Company and the scale-up program at BIC in terms of 5Ah MLP format and cylindrical cell builds which will progress over the June Quarter with support JDA execution.

Anteo X®™ and Anteo S™ sales conversion across the multiple businesses testing samples, will also remain a key commercial focus along with the dispatch of further samples, follow-up and sales conversion.

Securing of expertise, through a collaborative partnership that accelerates the Company's market entry of Anteo S™ is being worked on. In addition, USA market entry will be progressed, with potential distributor and agent identified along with regulatory approvals which would allow large-scale product import, in conjunction with comparisons of options for production in the USA.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

- ENDS -

Media and investor enquiries: on +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: Merrill Gray, CEO/MD, on + 61 7 3219 0085

For further information, please refer to our website www.anteotech.com

About AnteoTech - (ASX: ADO)

AnteoTech is a supplier of advanced material solutions to the battery materials and life sciences markets. We leverage our market leading binding chemistry platform technology to develop and commercialise solutions for our global customer base. From our patented cross linker product Anteo X™ and Separator coating product Anteo S to our next-generation high silicon anode formulations, Ultranode™, our Advanced Battery Technology business is applying its world-leading engineering expertise to address the growing demand for high performance, low cost, sustainable materials within the global battery market. Our Life Sciences business supplies advanced activation materials through our AnteoBind™ suite of products to leading developers and manufacturers of vaccines and diagnostic tests. Our products deliver more sensitive and reproducible results and on incorporation in 'point of care' tests, enable faster, more reliable and accurate test results wherever they are needed.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive our email alert service.

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to AnteoTech’ business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

AnteoTech Ltd

ABN

75 070 028 625

Quarter ended ("current quarter")

31 March 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	294	393
1.2 Payments for		
(a) research and development	(230)	(352)
(b) product manufacturing and operating costs	(3)	(8)
(c) advertising and marketing	(129)	(271)
(d) leased assets/occupancy	(194)	(622)
(e) staff costs	(1,071)	(2,930)
(f) administration and corporate costs	(251)	(1,130)
1.3 Dividends received (see note 3)		
1.4 Interest received	6	18
1.5 Interest and other costs of finance paid	(22)	(61)
1.6 Income taxes paid		
1.7 Government grants and tax incentives	0	2,589
1.8 Other (PPL wages)	0	10
1.9 Net cash from / (used in) operating activities	(1,600)	(2,364)

2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities		
(b) businesses		
(c) property, plant and equipment	(9)	(45)
(d) investments		
(e) intellectual property	(62)	(159)
(f) other non-current assets		

For personal use only

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment	0	0
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	Net cash from / (used in) investing activities	(71)	(204)
3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	3,808	3,808
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(289)	(289)
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	Net cash from / (used in) financing activities	3,519	3,519
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	1,443	2,340
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,600)	(2,364)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(71)	(204)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	3,519	3,519
4.5	Effect of movement in exchange rates on cash held	0	0
4.6	Cash and cash equivalents at end of period	3,291	3,291

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	2,291	1,443
5.2	Term deposits (3-month term)	1,000	
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	3,291	1,443

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	159
6.2	Aggregate amount of payments to related parties and their associates included in item 2	0

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

For personal use only

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities		
7.2 Credit standby arrangements		
7.3 Other (please specify)		
7.4 Total financing facilities		
7.5 Unused financing facilities available at quarter end		
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(1,600)
8.2 Cash and cash equivalents at quarter end (item 4.6)	3,291
8.3 Unused finance facilities available at quarter end (item 7.5)	0
8.4 Total available funding (item 8.2 + item 8.3)	3,291
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	2.1
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Scott Waddell
Company Secretary
20 April 2026

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.